Loading…
MedCI provides cross-border strategic consulting for the biopharma and medical device industries, specializing in in-licensing, out-licensing, M&A, and market intelligence. It connects North American and major Asian markets (Japan, South Korea, China) and acts as an extension of a client’s team to guide deals from strategy to closure with end-to-end support. With a cross-functional, culturally aware network, MedCI facilitates partnerships across licensing, distribution, joint ventures, and acquisitions in global life sciences.
AI named Medci in February 2026.